A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®-Reference-Cited by-同舟云学术

A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®

Published:2019-05-22 Issue:4 Volume:21 Page:
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Betts Alison,Haddish-Berhane Nahor,Shah Dhaval K.,van der Graaf Piet H.,Barletta Frank,King Lindsay,Clark Tracey,Kamperschroer Cris,Root Adam,Hooper Andrea,Chen Xiaoying

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

http://link.springer.com/content/pdf/10.1208/s12248-019-0332-z.pdf

Reference42 articles.

1. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73.

2. Lameris R, de Bruin RC, Schneiders FL, van Bergenenhenegouwen PM, Verheul HM, de Gruijl TD, et al. Bispecific antibody platforms for cancer immunotherapy. Crit Rev Oncol Hematol. 2014;92(3):153–65.

3. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69(12):4941–4.

4. Zimmerman Z, Maniar T, Nagorsen D. Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE(R)) antibody construct blinatumomab as a potential therapy. Int Immunol. 2015;27(1):31–7.

5. Oak E, Bartlett NL. Blinatumomab for the treatment of B-cell lymphoma. Expert Opin Investig Drugs. 2015;24(5):715–24.

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells;Nature Cancer;2024-09-11

2. General quasi-equilibrium multivalent binding model to study diverse and complex drug-receptor interactions of biologics;Journal of Pharmacokinetics and Pharmacodynamics;2024-08-17

3. Design of Crosslinking Antibodies For T-Cell Activation: Experimental and Computational Analysis of PD-1/CD137 Bispecific Agents;The AAPS Journal;2024-06-11

4. Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology;Clinical Pharmacology & Therapeutics;2024-06-02

5. Optimizing Clinical Translation of Bispecific T‐cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model;Clinical Pharmacology & Therapeutics;2024-05-15